Nancy Phelan - Moderna Director
| MRNA Stock | USD 107.89 3.43 3.28% |
Director
Ms. Nancy R. Phelan is Director of the Company. Ms. Phelan is an accomplished senior executive and thought leader with over 20 years success in the healthcare and biotech industries. Since October 2018, Ms. Phelan has served as Chief Business Officer, Innate Biologics, where she is responsible for strategy, business development and operations. Since January 2018, Ms. Phelan has served as an Executive Advisor to Innate Biologics. Previously, Ms. Phelan served as Senior Vice President, Commercial Growth at Outcome Health, since July 2017. Ms. Phelan has also served since April 2018 as an Independent Board Member for FemmePharma Consumer Healthcare, since August 2018 as an Advisory Board Member for Eved, and since May 2018 as a member of the Pharma Digital Health Roundtable Steering Committee. From September 2011 until December 2016, Ms. Phelan held roles of increasing responsibility for BristolMyers Squibb Company, including Vice President, U.S. Customer Strategy and Operations and Head, Worldwide Commercial Operations. Prior to her time at BMS, from October 2004 until September 2011, Ms. Phelan held leadership roles in global and U.S. marketing at Wyeth, which was acquired by Pfizer Inc. in 2009 since 2018.
| Age | 48 |
| Tenure | 6 years |
| Professional Marks | MBA |
| Address | 200 Technology Square, Cambridge, MA, United States, 02139 |
| Phone | 617 714 6500 |
| Web | https://www.modernatx.com |
Moderna Management Efficiency
The company has return on total asset (ROA) of (0.1197) % which means that it has lost $0.1197 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2859) %, meaning that it created substantial loss on money invested by shareholders. Moderna's management efficiency ratios could be used to measure how well Moderna manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -0.24. The current year's Return On Capital Employed is expected to grow to -0.26. At present, Moderna's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 23.1 B, whereas Other Current Assets are forecasted to decline to about 83.6 M.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Chaloemphong Mahawanitwong | Ginkgo Bioworks Holdings | 42 | |
| Cynthia Collins | Editas Medicine | 54 | |
| Sitthichai Kesornsombat | Ginkgo Bioworks Holdings | 51 | |
| Josh Suskin | Krystal Biotech | N/A | |
| Sangeeta Bhatia | Vertex Pharmaceuticals | 49 | |
| Phillip Donenberg | AVROBIO | 57 | |
| Akshay Vaishnaw | Editas Medicine | 55 | |
| JeanFrancois Formela | Intellia Therapeutics | 61 | |
| Gail Boudreaux | Novavax | 55 | |
| Moncef Slaoui | Intellia Therapeutics | 55 | |
| Carl Gordon | Intellia Therapeutics | 52 | |
| Rajiv Modi | Novavax | 56 | |
| Timothy Block | Hepion Pharmaceuticals | 61 | |
| Sirisak Piyathatsikun | Ginkgo Bioworks Holdings | 42 | |
| Alan Garber | Vertex Pharmaceuticals | 62 | |
| Thomas Adams | Hepion Pharmaceuticals | 74 | |
| Lloyd Carney | Vertex Pharmaceuticals | 56 | |
| Bruce Sachs | Vertex Pharmaceuticals | 58 | |
| Philip Vickers | AVROBIO | 58 | |
| John Brancaccio | Hepion Pharmaceuticals | 69 | |
| Ham Sukjaroenkraisri | Ginkgo Bioworks Holdings | N/A | |
Management Performance
| Return On Equity | -0.29 | ||||
| Return On Asset | -0.12 |
Moderna Leadership Team
Elected by the shareholders, the Moderna's board of directors comprises two types of representatives: Moderna inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Moderna. The board's role is to monitor Moderna's management team and ensure that shareholders' interests are well served. Moderna's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Moderna's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Larn Hwang, Chief Scientific Officer | ||
| Melanie MBA, Chief Officer | ||
| Daniel Geffken, Interim CFO | ||
| Stephane Bancel, CEO Director | ||
| Dave Johnson, Chief Officer | ||
| Lavina CFA, Senior Relations | ||
| Nancy Phelan, Director | ||
| Philip Ranker, Director | ||
| Joseph Ramelli, Independent Director | ||
| Noubar Afeyan, Independent CoFounder | ||
| Donald Williams, Independent Director | ||
| Colleen Hussey, Senior Communications | ||
| Patrick Bergstedt, Senior Vaccines | ||
| Robert Moscato, CEO | ||
| Isaac Blech, Director | ||
| Jerh Collins, Chief Officer | ||
| Juan Andres, Pres Expansion | ||
| Charbel MPH, Senior Science | ||
| Uli Hacksell, Chairman of the Board | ||
| Vuong Trieu, Chairman of the Board, CFO, Treasurer | ||
| Michael French, Chairman, CEO and Pres | ||
| Shannon Klinger, Chief Secretary | ||
| Brad Miller, Chief Officer | ||
| James Mock, Chief Officer | ||
| Erik Emerson, Chief Commercial Officer | ||
| John Reynders, Chief Officer | ||
| Melissa Moore, Chief Board | ||
| Stephen MD, President | ||
| Mihir Munsif, COO | ||
| Amit Shah, CFO | ||
| Tim Boris, Director | ||
| Philippe Calais, Director | ||
| Peter Weinstein, Chief Legal Officer | ||
| Stefan Loren, Lead Independent Director | ||
| Tracey Franklin, Chief Officer | ||
| Eric Teague, CFO | ||
| MD FAAP, Senior Development |
Moderna Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Moderna a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.29 | ||||
| Return On Asset | -0.12 | ||||
| Profit Margin | (0.69) % | ||||
| Operating Margin | 0 % | ||||
| Current Valuation | 32.55 B | ||||
| Shares Outstanding | 382.88 M | ||||
| Shares Owned By Insiders | 9.61 % | ||||
| Shares Owned By Institutions | 73.51 % | ||||
| Number Of Shares Shorted | 21.44 M | ||||
| Price To Earning | 6.37 X |
Moderna Investors Sentiment
The influence of Moderna's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Moderna. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Moderna's public news can be used to forecast risks associated with an investment in Moderna. The trend in average sentiment can be used to explain how an investor holding Moderna can time the market purely based on public headlines and social activities around Moderna. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Moderna's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Moderna's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Moderna's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Moderna.
Moderna Implied Volatility | 59.68 |
Moderna's implied volatility exposes the market's sentiment of Moderna stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Moderna's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Moderna stock will not fluctuate a lot when Moderna's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Moderna in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Moderna's short interest history, or implied volatility extrapolated from Moderna options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Moderna. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Moderna Stock refer to our How to Trade Moderna Stock guide.You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Complementary Tools for Moderna Stock analysis
When running Moderna's price analysis, check to measure Moderna's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moderna is operating at the current time. Most of Moderna's value examination focuses on studying past and present price action to predict the probability of Moderna's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moderna's price. Additionally, you may evaluate how the addition of Moderna to your portfolios can decrease your overall portfolio volatility.
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |
Is Moderna's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moderna. If investors know Moderna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moderna listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.85) | Earnings Share (12.33) | Revenue Per Share 17.927 | Quarterly Revenue Growth (0.45) | Return On Assets (0.12) |
The market value of Moderna is measured differently than its book value, which is the value of Moderna that is recorded on the company's balance sheet. Investors also form their own opinion of Moderna's value that differs from its market value or its book value, called intrinsic value, which is Moderna's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moderna's market value can be influenced by many factors that don't directly affect Moderna's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moderna's value and its price as these two are different measures arrived at by different means. Investors typically determine if Moderna is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moderna's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.